BostonGene AI framework identifies actionable targets in 65% of cancer of unknown primary cases at USCAP 2026
BostonGene presents multimodal AI CUP framework at USCAP 2026, identifying actionable targets in 65%+ of patients. Read the analysis.
Medical Devices & Diagnostics